Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease

NCT02523313 is registered in ClinicalTrials.gov with Prof. Dr. med. Dirk Schadendorf as lead sponsor.

NCT NCT02523313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02523313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease
Lead sponsor
Prof. Dr. med. Dirk Schadendorf
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2015
Completion date
June 27, 2021
Enrollment
167 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma